Vedanta Biosciences Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$82.4M
Industry:Biotech
Founded:N/A
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Vedanta Biosciences's estimated annual revenue is currently $13.5M per year.
  • Vedanta Biosciences received $27.0M in venture funding in December 2018.
  • Vedanta Biosciences's estimated revenue per employee is $155,000
  • Vedanta Biosciences's total funding is $82.4M.

Employee Data

  • Vedanta Biosciences has 87 Employees.
  • Vedanta Biosciences grew their employee count by -8% last year.
  • Vedanta Biosciences currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

The trillions of microbes that call us home the human microbiome - perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

keywords:Biotechnology,Healthcare,Pharmaceuticals

87

Number of Employees

$13.5M

Revenue (est)

1

Current Jobs

-8%

Employee Growth %

$82.4M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Daniel CoutoChief Operating OfficerEmail Available
Bernat OlleChief Executive OfficerEmail Available
David CraneSr. Qa ManagerEmail Available
Scott MichonskiSenior Manager Of Process DevelopmentEmail Available
Jeffrey GrauDirector Of FacilitiesEmail Available
Jack KyteSenior Director Human ResourcesEmail Available
Aaron BusholdQC ManagerEmail Available
Marie AllenSr Director Quality
Jil UlrichAssociate Director of CMC OperationsEmail Available
Kris IrelandDirector Of ManufacturingEmail Available

Vedanta Biosciences News

09/07/2019 - Human Microbiome Therapeutics Market 2019 Business ...

Human Microbiome Therapeutics Market 2019 Business Scenario – Enterome Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences.

09/08/2019 - Human Microbiome Market: Rising Incidence of Metabolic ...

... Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences, Enterome, Biosciences, and Synthetic Biologics, Inc.

09/05/2019 - Analyst Predict: Human Microbiome Market expecting to grow ...

Top Players Profiled in this Report includes, Enterome Bioscience ... Second Genome Inc. (U.S.), Yakult (Japan), Vedanta BioSciences (U.S.), ...

Vedanta Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-06-07$50.0MUndisclosedArticle
2018-12-26$27.0MCMultipleArticle

Vedanta Biosciences Executive Hires

DateNameTitleReference
2016-03-17Bruce L RobertsChief Scientific OfficerArticle
2016-04-15Daniel E. CoutoSVP Development and ManufacturingArticle